Rituxan rituximab chimeric monoclonal antibody against CD20: Marketed

IDPH presented one-year follow-up data from 166 patients treated in its Phase III trial. Participants received 375 mg/m2 weekly for 4 infusions. A total of 6 percent showed complete responses and 42 percent showed partial responses. Median time to progression for responders was 13.2 months. Median duration of response was 11.6 months, compared to 12 months seen with chemotherapy (p=0.072). Of 80 responders, 22 remain in remission.

Separately, a 60-patient Phase II trial determined safety and efficacy of retreatment with Rituxan after disease progression. Safety was similar to that for initial Rituxan treatment. Among 56 evaluable patients, the overall response rate was 41 percent, including 7 complete responses and 16 partial responses. Median time to progression and duration of response had not been reached after 10 and 7.7 months, respectively. ...